<DOC>
	<DOCNO>NCT00992355</DOCNO>
	<brief_summary>This randomize controlled trial compare two regimen topical therapy : - tobramycin 0.3 % - dexamethasone 0.1 % ( TobraDex® , Alcon ) , one drop four times/day - combination tobramycin 0.3 % - dexamethasone 0.1 % ( TobraDex® , Alcon ) , one drop four times/day , plus Ketorolac tromethamine 0.5 % ( Acular® , Allergan ) , one drop three times/day . The topical treatment administer 28 day phacoemulsification . Patients independently assess two ophthalmologist . On day 28 , patient evaluate - corneal edema - conjunctival redness - anterior chamber reaction . Moreover , case necessitate continuation treatment compare two group day 28 42 .</brief_summary>
	<brief_title>Tobramycin-Dexamethasone Versus Tobramycin-Dexamethasone Plus Ketorolac After Phacoemulsification Surgery</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Phacoemulsification ( due cataract ) Uneventful phacoemulsification surgery Disruption anterior lens capsule Agerelated macular degeneration Proliferative diabetic retinopathy Glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Cataract</keyword>
	<keyword>Phacoemulsification</keyword>
	<keyword>Treatment duration</keyword>
</DOC>